Get the Stockscreener App
0.3401
5.98%
0.0199
Bioatla Inc stock is traded at $0.3401, with a volume of 1.67M.
It is up +5.98% in the last 24 hours and down -49.36% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.3202
Open:
$0.3418
24h Volume:
1.67M
Relative Volume:
0.94
Market Cap:
$21.73M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.1313
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
+5.32%
1M Performance:
-49.36%
6M Performance:
-15.12%
1Y Performance:
-31.39%
1-Day Range:
$0.3268
$0.3535
1-Week Range:
$0.29
$0.3535
52-Week Range:
$0.2601
$1.43
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.3393 | 20.51M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.58 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.82 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.94 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.26 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.94 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
Aug Chart Watch: What is the dividend yield of BioAtla IncWatch List & Technical Buy Zone Confirmations - baoquankhu1.vn
Whale Trades: Is BioAtla Inc forming bullish engulfing patternsJuly 2025 Price Swings & Risk Controlled Daily Plans - baoquankhu1.vn
What analysts say about BioAtla Inc. stockTrade Risk Assessment & Free Low Drawdown Momentum Trade Ideas - bollywoodhelpline.com
BioAtla stock slips premarket after early pop as investors weigh $40M SPV deal for phase 3 cancer trial - MSN
Aug Decliners: Can BioAtla Inc deliver consistent dividendsEarnings Overview Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Big Money Moves: Should you buy the dip on BioAtla IncJuly 2025 Update & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Brokerages Set BioAtla, Inc. (NASDAQ:BCAB) Target Price at $4.00 - Defense World
BioAtla faces Nasdaq delisting over share price rule - MSN
BioAtla (NASDAQ:BCAB) Coverage Initiated by Analysts at Rodman & Renshaw - Defense World
VIX Spike: Can BioAtla Inc deliver consistent dividendsJuly 2025 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
BioAtla Creates Super-Voting Share to Advance Reverse Split - The Globe and Mail
BioAtla stock initiated with Buy rating at Rodman & Renshaw - Investing.com
Why BioAtla Inc. stock remains resilientJuly 2025 Gainers & Real-Time Buy Signal Notifications - Улправда
BioAtla, Inc.Common Stock (NQ: BCAB - FinancialContent
Is BioAtla Inc. stock undervalued vs historical averages2025 Big Picture & Consistent Growth Stock Picks - ulpravda.ru
Is BioAtla Inc. stock attractive for hedge funds2025 Volatility Report & Daily Stock Trend Reports - Улправда
Is BioAtla Inc. stock dividend yield sustainable2025 Stock Rankings & Entry Point Confirmation Alerts - Улправда
What risks investors should watch in BioAtla Inc. stockEarnings Risk Report & Fast Entry Momentum Trade Alerts - Улправда
How BioAtla Inc. stock performs in rising dollar environmentMarket Volume Summary & Short-Term Trading Alerts - Улправда
How rising interest rates impact BioAtla Inc. stock2025 EndofYear Setup & Free Community Consensus Stock Picks - ulpravda.ru
Will BioAtla Inc. stock maintain momentum in 2025Volatility Index Analysis & Low Cost Portfolio Growth - ulpravda.ru
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - RTTNews
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
BioAtla, GATC Health Advance Ozuriftamab Vedotin Into Phase 3 OPSCC Trial Via SPV Deal - Voice Of HealthCare
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Asianet Newsable
BioAtla’s Phase 3 Cancer Trial Is “AI-Backed”. Just Not in the Way You Think - AIM Media House
BioAtla and GATC Health to advance Oz-V in Phase III trial - Yahoo Finance
BioAtla announces $40 million oncology SPV investment deal - MSN
Bioatla stock rises after $40 million SPV deal to advance cancer drug - Investing.com Australia
BioAtla secures $40 million for phase 3 cancer drug development By Investing.com - Investing.com Nigeria
BioAtla (BCAB) Teams Up with GATC Health for $40M SPV Transaction to Tackle OPSCC with Oz-V - parameter.io
Bioatla stock rises after $40 million SPV deal to advance cancer drug By Investing.com - Investing.com South Africa
BioAtla Announces $40 Million Oncology SPV Investment Deal - TipRanks
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle Transaction to Advance Ozuriftamab Vedotin into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma - Investing News Network
BioAtla Signs Multiple Material Agreements - TradingView — Track All Markets
BioAtla secures $40 million for phase 3 cancer drug development - Investing.com India
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - The Manila Times
BioAtla Secures $5 Million Initial Funding for Phase 3 Trial of Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma - Quiver Quantitative
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.22%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):